Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel O Persky

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Viruses|August 10, 2021
Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell LymphomaShariful Islam, Claudia M Espitia, Daniel O Persky, et al.
Blood Advances|October 27, 2020
Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapyShariful Islam, Claudia M Espitia, Daniel O Persky, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|August 25, 2009
High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphomaDaniel O Persky, Craig H Moskowitz, Alexander Filatov, et al.
International Journal of Cancer|July 29, 2011
AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomasWenqing Qi, Xiaobing Liu, Laurence S Cooke, et al.
Molecular Imaging|May 4, 2016
Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRIPaul J Akhenblit, Neale T Hanke, Alexander Gill, et al.
Cancer|July 27, 2012
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350Daruka Mahadevan, Joseph M Unger, Catherine M Spier, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2018
Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination TherapyShahram Mori, Rushang D Patel, Sarfraz Ahmad, et al.
Leukemia Research|November 17, 2012
Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatmentWenqing Qi, Catherine Spier, Xiaobing Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphomaDaruka Mahadevan, Amy Stejskal, Laurence S Cooke, et al.
Biochemical Pharmacology|February 5, 2011
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphomaWenqing Qi, Laurence S Cooke, Xiaobing Liu, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Viruses|August 10, 2021
Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell LymphomaShariful Islam, Claudia M Espitia, Daniel O Persky, et al.
Blood Advances|October 27, 2020
Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapyShariful Islam, Claudia M Espitia, Daniel O Persky, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|August 25, 2009
High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphomaDaniel O Persky, Craig H Moskowitz, Alexander Filatov, et al.
International Journal of Cancer|July 29, 2011
AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomasWenqing Qi, Xiaobing Liu, Laurence S Cooke, et al.
Molecular Imaging|May 4, 2016
Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRIPaul J Akhenblit, Neale T Hanke, Alexander Gill, et al.
Cancer|July 27, 2012
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350Daruka Mahadevan, Joseph M Unger, Catherine M Spier, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2018
Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination TherapyShahram Mori, Rushang D Patel, Sarfraz Ahmad, et al.
Leukemia Research|November 17, 2012
Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatmentWenqing Qi, Catherine Spier, Xiaobing Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphomaDaruka Mahadevan, Amy Stejskal, Laurence S Cooke, et al.
Biochemical Pharmacology|February 5, 2011
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphomaWenqing Qi, Laurence S Cooke, Xiaobing Liu, et al.
Pageof 5